Therefore, we cannot conclude whether the alterations observed concurrently with sensitizing EGFR mutations in NSCLC (Supplementary Table S5) were mediating primary or acquired resistance to EGFR inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.